- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04799366
Contractile Properties of Hypertrofic Muscles in Patients With Non-Dystrophic Myotonia
In myotonia congenita (MC), mutations in the CLCN1 gene coding a key chloride channel expressed in muscle cells cause myotonia. On examination, the myotonia can be demonstrated as delayed muscle relaxation of muscle contractions after mechanical stimulations. Existing literature describe no muscle weakness in MC patients, however a recent muscle MRI study in non-dystrophic myotonia patients found structural abnormalities in affected muscles when examined using T1 and STIR imaging. The question remains whether the signs of structural changes in the muscle are merely due to the myotonia, or long-term effects of elevated stress of the tissue, and if so, whether those changes lead to clinically significant loss of contractile properties of the muscle.
This study examines if the contractile properties of myotonic muscles are impaired in MC patients. 40 patients with Thomsens disease (n=20) and Beckers disease (n=20), respectively, will be included along with 20 healthy controls. Peak muscle torque is measured in the hand by hand dynamometer and in the thigh and calf muscles with a Biodex System 4 Pro Dynamometer and the cross-sectional area of the muscles are examined on T1-weighed and Dixon-MRI-scan. With the obtained data peak torque in strength tests, muscle hypertrophy, fat fraction in muscle tissue and contractility of the muscles, compared with healthy controls, will be assessed.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Laura Jacobsen, BSc
- Phone Number: +4535456135
- Email: laura.noerager.jacobsen.01@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark
- Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
40 patients (Thomsens MC, n=20; Beckers MC, n=20) will be included along with 20 healthy age- and gender-matched controls. Inclusion criteria are age >18 years, verified MC diagnosis. Exclusion criteria areknown competing disorders that can interfere with the results (ie. muscular diseases or arthritis) or MRI contraindications.
Before participation patients are asked about medication status. Participants who are treated for their myotonic symptoms with either Mexiletin or Lamotrigin are asked to pause their medication four days prior to participation.
All patients will be asked to evaluate the severity of their myotonic symptoms using the MBS (Myotonic Behaviour Scale) rating from 1 (least severe) to 6 (most severe).
Description
Inclusion Criteria:
- Age <18 years
- Molecularly verified MC (Thomsens or Beckers disease)
Exclusion Criteria:
- Conditions that may impair results of the study, evaluated by the investigator
- Clausphobia
- Pregnancy or breastfeeding
- Metallic objects in and around the body that are not MR-compatible
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
MC
MC patients with either dominant (Thomsens) or recessive (Becker) myotonia.
|
Healthy Controls
Healthy controls age- and gender matched.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Contractile properties
Time Frame: 1 year
|
To investigate if contractile properties of the muscles are impaired in MC patients compared with healthy controls.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measuring muscle hypertrophy in upper and lower limbs
Time Frame: 1 year
|
Visualizing and measuring hypertrophy on MRI of affected muscles in the forearm, thigh and calf of MC patients compared with muscles in healthy controls.
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-18023049-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Dystrophic Myotonia
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedNon Dystrophic MyotoniaNetherlands
-
University College, LondonRecruitingNon-Dystrophic MyotoniaUnited Kingdom
-
Richard Barohn, MDCompletedNon-Dystrophic Myotonia | MyotoniaUnited States, Canada, Italy, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedMyotonia Congenita | Paramyotonia Congenita | Non-dystrophic MyotoniasFrance
-
Centre Hospitalier Universitaire de NiceNot yet recruiting
-
Grete Andersen, MDRegion Capital Denmark; GCP-Copenhagen; Danish Region; Lupin Atlantis Holdings... and other collaboratorsRecruiting
-
Rigshospitalet, DenmarkRecruitingNondystrophic Myotonia | Paramyotonia CongenitaDenmark
-
Krystal Biotech, Inc.CompletedDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis BullosaUnited States
-
Richard Barohn, MDRare Diseases Clinical Research Network; Office of Rare Diseases (ORD)CompletedMyotonic Disorders | Myotonia Congenita | Nondystrophic MyotoniasCanada, United States, United Kingdom